Findings from the first two years of a five-year,real-world study, which was published in the Journal of Clinical Oncology (JCO)reveal that Comprehensive Genomic Profiling (CGP), when done early in a cancerpatient’s diagnosis, leads to better personalized treatment and patientoutcomes.

This new research by Providence, Illumina, and Microsoftshowed that using CGP testing finds more useful genetic changes than an older50-gene test. Patients tested with CGP were more likely to get targetedtreatments and lived longer when tested at diagnosis. However, not all patientsget CGP testing, so there are still some gaps in who benefits from this approach.

‍

Called Prevention4Me, the survey-based assessment has already proven integral to proactive early cancer detection, as well as determining eligibility for enhanced breast cancer screening and/or genetic testing. This personaland family history screening tool, which was developed by Providence Genomics, gives people and their doctors anindividualized assessment of possible risk for developing breast and othercancers. It is free and offered to anyone – both women and men between ages 25and 80 – when they make a mammogram appointment with Providence ComprehensiveBreast Center.

‍

A multi-cancer screeningtest from Providence partner GRAIL detected cancer when other methods didn't.

‍

Providence Cancer Institute of Oregon and Swedish Cancer Institute were invited to join an international data-sharing consortium of leading cancer centers working on a groundbreaking registry of publicly accessible genomic data. The American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange, or Project GENIE, is designed to boost oncology research by making high quality, de-identified (anonymous) genomic sequencing data and clinical outcomes from cancer patients accessible to the global cancer research community.  

On October 28th, 2022, Providence Genomics released preliminary Geno4ME study findings. Geno4ME “Genomic Medicine for EVERYONE” is a population genomics program that uses Whole Genome Sequencing (WGS) to identify if a patient has a genetic predisposition to certain diseases and how their DNA will affect their response to certain medications.

Providence Genomics will be presenting five innovative papers at this event on genomic profiling, implementing a virtual tumor board, and more.

Presenter: Carlo Bifulco, MD, Medical Director, Providence Medical Genomics, and other healthcare industry panelists

‍

Josiah Wagner, Senior Clinical Research Scientist at Providence, will be speaking on Geno4ME and the establishment of an equitable whole-genome sequencing-based platform for clinical screening in a large healthcare system.

Presenter: Carlo Bifulco, MD, Medical Director, Providence Medical Genomics

The genomic health revolution is here—and you can be a part of it. Introducing the inaugural Illumina Genomics Forum, our premier global event advancing the positive impact of genomic health.

HLTH (health) is the leading platform bringing together the entire health ecosystem, focused on health innovation and transformation.

Panelists Include: Dr. Ora Gordon, Clinical Director of Providence’s Population Health Genomics Program

Time: 1-2 PM EDT, Virtual presentation

‍

Armed with a passion to eradicate the deadliest of all cancers, Eric Tran, Ph.D., and Rom Leidner, M.D., have pioneered a second-generation adoptive cell therapy using genetically engineered T cells. Read about their innovative work in the New England Journal of Medicine article Neoantigen T-Cell Receptor-Gene Therapy in Pancreatic Cancer.